AM630 is an inverse agonist at the human cannabinoid CB1 receptor

被引：46
作者：
Landsman, RS
Makriyannis, A
Deng, HF
Consroe, P
Roeske, WR
Yamamura, HI [1 ]
机构：
[1] Univ Arizona, Hlth Sci Ctr, Coll Med, Dept Pharmacol, Tucson, AZ 85724 USA
[2] Univ Arizona, Hlth Sci Ctr, Dept Pharmacol & Toxicol, Tucson, AZ 85724 USA
[3] Univ Arizona, Hlth Sci Ctr, Dept Biochem, Tucson, AZ 85724 USA
[4] Univ Arizona, Hlth Sci Ctr, Dept Med, Tucson, AZ 85724 USA
[5] Univ Arizona, Hlth Sci Ctr, Dept Psychiat, Tucson, AZ 85724 USA
[6] Univ Arizona, Hlth Sci Ctr, Program Neurosci, Tucson, AZ 85724 USA
[7] Univ Connecticut, Sch Pharm, Storrs, CT 06269 USA
来源：
LIFE SCIENCES | 1998年 / 62卷 / 09期
关键词：
human cannabinoid CB1 receptor; inverse agonism; AM630; WIN 55,212-2; GTP gamma S; CHO cells; inverse agonist; negative intrinsic activity;
D O I：
10.1016/S0024-3205(97)01187-9
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
The present investigation examines WIN 55,212-2 and AM630 at the cloned human cannabinoid CB1, receptor stably expressed in Chinese hamster ovary (CHO) cells. The effect of various concentrations of WIN 55,212-2 and AM630 on basal [S-35]GTP gamma S binding to cell membranes was determined. WIN 55,212-2 (100 mu M) stimulated basal [S-35]GTP gamma S binding 77.9% with an EC50 value of 0.36 mu M. Conversely, AM630 (100 mu M) inhibited basal [S-35]GTP gamma S binding by 20.9% with an EC50 value of 0.90 mu M These results show that WIN 55,212-2 is an agonist and AM630 is an inverse agonist in this system. (C) 1998 Elsevier Science Inc.
引用
收藏
页码：PL109 / PL113
页数：5
相关论文
共 50 条
[1]   AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor [J].
Bolognini, Daniele ;
Cascio, Maria Grazia ;
Parolaro, Daniela ;
Pertwee, Roger G. .
BRITISH JOURNAL OF PHARMACOLOGY, 2012, 165 (08) :2561-2574
[2]   SR141716A is an inverse agonist at the human cannabinoid CB1 receptor [J].
Landsman, RS ;
Burkey, TH ;
Consroe, P ;
Roeske, WR ;
Yamamura, HI .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 334 (01) :R1-R2
[3]   The cannabinoid CB1 receptor inverse agonist AM 251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats [J].
Hodge, Janel ;
Bow, Joshua P. ;
Plyler, Kimberly S. ;
Vemuri, V. Kiran ;
Wisniecki, Ania ;
Salamone, John D. ;
Makriyannis, Alexandros ;
McLaughlin, Peter J. .
BEHAVIOURAL BRAIN RESEARCH, 2008, 193 (02) :298-305
[4]   Behavioral effects of the novel potent cannabinoid CB1 agonist AM 4054 [J].
McLaughlin, Peter J. ;
Thakur, Ganesh A. ;
Vemuri, V. Kiran ;
McClure, Evan D. ;
Brown, Cara M. ;
Winston, Keisha M. ;
Wood, JodiAnne T. ;
Makriyannis, Alexandros ;
Salamone, John D. .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2013, 109 :16-22
[5]   Crystal Structure of the Human Cannabinoid Receptor CB1 [J].
Hua, Tian ;
Vemuri, Kiran ;
Pu, Mengchen ;
Qu, Lu ;
Han, Gye Won ;
Wu, Yiran ;
Zhao, Suwen ;
Shui, Wenqing ;
Li, Shanshan ;
Korde, Anisha ;
Laprairie, Robert B. ;
Stahl, Edward L. ;
Ho, Jo-Hao ;
Zvonok, Nikolai ;
Zhou, Han ;
Kufareva, Irina ;
Wu, Beili ;
Zhao, Qiang ;
Hanson, Michael A. ;
Bohn, Laura M. ;
Makriyannis, Alexandros ;
Stevens, Raymond C. ;
Liu, Zhi-Jie .
CELL, 2016, 167 (03) :750-+
[6]   CB1 Receptor Inverse Agonist Pharmacotherapy for Metabolic Disorders [J].
Fong, Tung M. ;
Addy, Carol ;
Erondu, Ngozi ;
Heymsfield, Steven B. .
DRUG DEVELOPMENT RESEARCH, 2009, 70 (08) :566-576
[7]   The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: Evidence from postmortem human brain [J].
Erdozain, A. M. ;
Diez-Alarcia, R. ;
Meana, J. J. ;
Callado, L. F. .
BIOCHEMICAL PHARMACOLOGY, 2012, 83 (02) :260-268
[8]   Toward the Design of Cannabinoid CB1 Receptor Inverse Agonists and Neutral Antagonists [J].
Reggio, Patricia H. .
DRUG DEVELOPMENT RESEARCH, 2009, 70 (08) :585-600
[9]   Signal transduction of the CB1 cannabinoid receptor [J].
Turu, Gabor ;
Hunyady, Laszlo .
JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2010, 44 (02) :75-85
[10]   Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity [J].
Franks, Lirit N. ;
Ford, Benjamin M. ;
Prather, Paul L. .
FRONTIERS IN PHARMACOLOGY, 2016, 7
12345